The Effect of Pandemic on Children With Cerebral Palsy

October 20, 2022 updated by: Sevda Adar

Investigation of the Effect of Covid-19 Pandemic on Children With Cerebral Palsy

Cerebral Palsy (CP), is the most common cause of physical disability that begins in childhood and lasts throughout life, affecting 1 in 500 newborns, with an estimated prevalence of 17 million worldwide.

Social isolation, economic conditions, interruption of treatments, etc. may cause physical, mental, behavioral and psychosocial changes in children with cerebral palsy. Discontinuing regular physiotherapy can worsen functional skills and cause complications in children with cerebral palsy. Our aim in this study is to investigate the sustainability of the treatments of children with cerebral palsy during the pandemic period, their physical and psychosocial effects, and the relationship between their parents' fear of covid-19.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
    • Afyon
      • Merkez, Afyon, Turkey
        • Sevda Adar

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

-Parents of children under the age of 18 with cerebral palsy who applied to our hospital between 01.01.2014-31.01.2021

Description

Inclusion Criteria:

  • Parents of children under the age of 18 with cerebral palsy who applied to our hospital between 01.01.2014-31.01.2021

Exclusion Criteria:

  • Parents of Cerebral Palsy Patients over 18 years of age
  • Parents who cannot be reached by phone
  • Parents who do not agree to fill out the questionnaire

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Other

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation Survey
Time Frame: First day
A questionnaire form consisting of 19 questions and 3 parts prepared by the authors in the light of the information obtained during the clinical observation process of children with cerebral palsy will be used.
First day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Covid-19 Fear Scale
Time Frame: First day
Parents' fear of COVID-19 will be evaluated with the COVID-19 fear scale consisting of 7 questions. The items of the scale were created on the basis of a comprehensive review of existing scales on fear, expert evaluations, and participant interviews.
First day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sevda Adar

Investigators

  • Study Chair: PETEK ŞARLAK KONYA, Afyonkarahisar Health Sciences University
  • Study Chair: ALİ İZZET AKÇİN, Afyonkarahisar Health Sciences University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 15, 2021

Primary Completion (Actual)

July 30, 2021

Study Completion (Actual)

August 10, 2021

Study Registration Dates

First Submitted

July 12, 2021

First Submitted That Met QC Criteria

July 12, 2021

First Posted (Actual)

July 21, 2021

Study Record Updates

Last Update Posted (Actual)

October 21, 2022

Last Update Submitted That Met QC Criteria

October 20, 2022

Last Verified

October 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SASP21

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebral Palsy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe